Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

NCT07175051 is registered in ClinicalTrials.gov with University of Illinois at Chicago as lead sponsor.

NCT NCT07175051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07175051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
Lead sponsor
University of Illinois at Chicago
Phase
Phase 2
Overall status
Recruiting
Start date
April 8, 2026
Completion date
October 31, 2030
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

albuminuria, sickle cell anemia (hbss, or hbsβ-thalassemia0)